3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Prostatic Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
8
Leukemia
8
Lymphoma, Non-Hodgkin
7
Burkitt Lymphoma
5
Hodgkin Disease
4
Neoplasm Metastasis
3
Lymphoma, Large-Cell, Immunoblastic
3
Leukemia, Biphenotypic, Acute
3
Dendritic Cell Sarcoma, Interdigitating
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Urogenital Neoplasms
1
Thymoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Myasthenia Gravis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Prednisolone
×
Clear all
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled